Balázs Gulyás
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Balázs Gulyás has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Christer Halldin
5 shared publicationsLars Farde
5 shared publicationsPer E. Roland
Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
4 shared publicationsJudit Sóvágó
Department of Clinical Neuroscience, Karolinska Institutet, Psychiatry Section, S-171 76 Stockholm, Sweden
3 shared publicationsÁdám Vas
3 shared publicationsA. Cowey
Department of Experimental Psychology, Oxford University, Oxford OX1 3UD, United Kingdom
2 shared publications
Latest Publications
- 1 July 2006
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 246 (1-2) , 85-94
Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas
- 1 July 2006
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 246 (1-2) , 85-94
Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas
- 1 February 2006
- Published by Springer Nature in Neurochemical Research
- Vol. 31 (2) , 157-166
Continuous Monitoring of Post Mortem Temperature Changes in the Human Brain
- 1 February 2006
- Published by Springer Nature in Neurochemical Research
- Vol. 31 (2) , 157-166
Continuous Monitoring of Post Mortem Temperature Changes in the Human Brain
- 1 March 2005
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 229-230, 219-223
[11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies
- 1 March 2005
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 229-230, 219-223
[11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies
- 1 October 2004
- Published by Elsevier in Neurochemistry International
- Vol. 45 (5) , 609-617
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, 611C9RGH-1756 in the monkey brain
- 1 October 2004
- Published by Elsevier in Neurochemistry International
- Vol. 45 (5) , 609-617
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, 611C9RGH-1756 in the monkey brain
- 1 October 2004
- Published by Elsevier in Neurochemistry International
- Vol. 45 (5) , 773-781
Joint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor?transporter correlation using PET data
- 1 October 2004
- Published by Elsevier in Neurochemistry International
- Vol. 45 (5) , 773-781
Joint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor?transporter correlation using PET data
- 1 June 2004
- Published by Elsevier in Neurochemistry International
- Vol. 44 (8) , 595-600
The putative pheromone androstadienone activates cortical fields in the human brain related to social cognition
- 1 June 2004
- Published by Elsevier in Neurochemistry International
- Vol. 44 (8) , 595-600
The putative pheromone androstadienone activates cortical fields in the human brain related to social cognition
- 26 November 2003
- Published by Wiley in Human Brain Mapping
- Vol. 21 (1) , 26-33
Feature uncertainty activates anterior cingulate cortex
In visual discrimination tasks, the relevant feature to discriminate is defined before stimulus presentation. In feature uncertainty tasks, a cue about the relevant feature is provided after stimulus offset. We used 15O‐butanol positron emission tomography (PET) in order to investigate brain activation during a feature uncertainty task. There was greater activity during the feature uncertainty task, compared with stimulus detection and discrimination of orientation and spatial frequency, in the lateral and medial prefrontal cortex, the cuneus, superior temporal and inferior parietal cortex, cortical motor areas, and the cerebellum. The most robust and consistent activation was observed in the dorsal anterior cingulate cortex (Brodmann area 32; x = 0 y = 16, z = 40). The insula, located near the claustrum (x = −38, y = 8, z = 4), was activated during the discrimination tasks compared with the feature uncertainty condition. These results suggest that the dorsal anterior cingulate cortex is important in feature uncertainty conditions, which include divided attention, expectancy under uncertainty, and cognitive monitoring. Hum. Brain Mapp. 21:26–33, 2004.
- 26 November 2003
- Published by Wiley in Human Brain Mapping
- Vol. 21 (1) , 26-33
Feature uncertainty activates anterior cingulate cortex
In visual discrimination tasks, the relevant feature to discriminate is defined before stimulus presentation. In feature uncertainty tasks, a cue about the relevant feature is provided after stimulus offset. We used 15O‐butanol positron emission tomography (PET) in order to investigate brain activation during a feature uncertainty task. There was greater activity during the feature uncertainty task, compared with stimulus detection and discrimination of orientation and spatial frequency, in the lateral and medial prefrontal cortex, the cuneus, superior temporal and inferior parietal cortex, cortical motor areas, and the cerebellum. The most robust and consistent activation was observed in the dorsal anterior cingulate cortex (Brodmann area 32; x = 0 y = 16, z = 40). The insula, located near the claustrum (x = −38, y = 8, z = 4), was activated during the discrimination tasks compared with the feature uncertainty condition. These results suggest that the dorsal anterior cingulate cortex is important in feature uncertainty conditions, which include divided attention, expectancy under uncertainty, and cognitive monitoring. Hum. Brain Mapp. 21:26–33, 2004.
- 8 October 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (7) , 753-759
Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study
- 8 October 2002
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 29 (7) , 753-759
Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study
- 7 May 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (8) , 1031-1038
Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine
Direct information on the distribution of a drug requires measurements in various tissues. Such data have until now been obtained in animals, or have indirectly been calculated from plasma measurements in humans using mathematical models. Here we suggest the use of positron emission tomography (PET) as a method to obtain direct measurements of drug distribution in the human body. The distribution in body and brain of vinpocetine, a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases, was followed after oral administration. Vinpocetine was labelled with carbon-11 and radioactivity was measured by PET in stomach, liver, brain and kidney in six healthy volunteers. The radioactivity in blood and urine as well as the fractions of [11C]vinpocetine and labelled metabolites in plasma were also determined. After oral administration, [11C]vinpocetine appeared immediately in the stomach and within minutes in the liver and the blood. In the blood the level of radioactivity continuously increased until the end of the measurement period, whereas the fraction of the unchanged mother compound decreased. Radioactivity uptake and distribution in the brain were demonstrable from the tenth minute after the administration of the labelled drug. Brain distribution was heterogeneous, similar to the distribution previously reported after intravenous administration. These findings indicate that vinpocetine, administered orally in humans, readily enters the bloodstream from the stomach and gastrointestinal tract and, consequently, passes the blood-brain barrier and enters the brain. Radioactivity from [11C]vinpocetine was also demonstrated in the kidneys and in urine, indicating that at least a part of the radioactive drug and labelled metabolites is eliminated from the body through the kidneys. This study is the first to demonstrate that PET might be a useful, direct and non-invasive tool to study the distribution and pharmacokinetics of orally administered labelled CNS drugs in the living human body.
- 7 May 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (8) , 1031-1038
Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine
Direct information on the distribution of a drug requires measurements in various tissues. Such data have until now been obtained in animals, or have indirectly been calculated from plasma measurements in humans using mathematical models. Here we suggest the use of positron emission tomography (PET) as a method to obtain direct measurements of drug distribution in the human body. The distribution in body and brain of vinpocetine, a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases, was followed after oral administration. Vinpocetine was labelled with carbon-11 and radioactivity was measured by PET in stomach, liver, brain and kidney in six healthy volunteers. The radioactivity in blood and urine as well as the fractions of [11C]vinpocetine and labelled metabolites in plasma were also determined. After oral administration, [11C]vinpocetine appeared immediately in the stomach and within minutes in the liver and the blood. In the blood the level of radioactivity continuously increased until the end of the measurement period, whereas the fraction of the unchanged mother compound decreased. Radioactivity uptake and distribution in the brain were demonstrable from the tenth minute after the administration of the labelled drug. Brain distribution was heterogeneous, similar to the distribution previously reported after intravenous administration. These findings indicate that vinpocetine, administered orally in humans, readily enters the bloodstream from the stomach and gastrointestinal tract and, consequently, passes the blood-brain barrier and enters the brain. Radioactivity from [11C]vinpocetine was also demonstrated in the kidneys and in urine, indicating that at least a part of the radioactive drug and labelled metabolites is eliminated from the body through the kidneys. This study is the first to demonstrate that PET might be a useful, direct and non-invasive tool to study the distribution and pharmacokinetics of orally administered labelled CNS drugs in the living human body.
- 1 February 2001
- Published by Elsevier in Brain Research Bulletin
- Vol. 54 (3) , 319-328
Neural networks for internal reading and visual imagery of reading: a PET study
- 1 February 2001
- Published by Elsevier in Brain Research Bulletin
- Vol. 54 (3) , 319-328
Neural networks for internal reading and visual imagery of reading: a PET study